MedTrace Logo

Validation of TAD in HER-2 with More Than 2 Lymph Nodes

NCT06821490 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2025-02-12

No results posted yet for this study

Summary

The main objective of the study is to validate the DAT technique in patients with Her2-positive breast cancer who have more than two positive axillary lymph nodes at diagnosis. After receiving adequate oncological treatment and axillary assessment by ultrasound for complete radiological response, DAT and Berg level I and II lymphadenectomy will be performed to assess false negatives and positives, as well as their sensitivity and specificity.

Conditions

  • Breast Carcinoma Metastatic in Lymph Node
  • HER2 Positive Breast Carcinoma

Interventions

PROCEDURE

Targeted axillary dissection and subsequently a lymphadenectomy

Selective sentinel lymph node biopsy is performed, along with biopsy of the node marked at diagnosis. Subsequently, a lymphadenectomy is performed, with the three samples separated for pathological study during the same surgical procedure

Sponsors & Collaborators

  • Fundación para la Investigación del Hospital Clínico de Valencia

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-30
Primary Completion
2026-01-30
Completion
2026-02-28

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06821490 on ClinicalTrials.gov